Bladder Cancer

>

Latest News

Intravesical Mitomycin Demonstrates Significant Duration of Response in NMIBC
Intravesical Mitomycin Demonstrates Significant Duration of Response in NMIBC

October 30th 2024

The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer

October 28th 2024

Bladder Cancer Indication of Sacituzumab Govitecan Withdrawn in US
Bladder Cancer Indication of Sacituzumab Govitecan Withdrawn in US

October 21st 2024

FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer
FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer

October 16th 2024

SunRISe-2 Study of TAR-200 Plus Cetrelimab in MIBC Discontinues
SunRISe-2 Study of TAR-200 Plus Cetrelimab in MIBC Discontinues

October 8th 2024